Characteristics and prognosis of children with recurrent T-cell acute lymphoblastic leukemia: a long-term follow-up report in China

References

• Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938–2948.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019;20(3):e142–e54. Mar
   PubMed Web of Science ®Google Scholar
• Möricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265–284.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Blonquist TM, Harris MH, et al. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL consortium protocol 05-001. Blood Adv. 2018;2(12):1449–1458.
   PubMed Web of Science ®Google Scholar
• Patrick K, Vora A. Update on biology and treatment of T-cell acute lymphoblastic leukaemia. Curr Opin Pediatr. 2015;27(1):44–49.
   PubMed Web of Science ®Google Scholar
• Matloub Y, Stork L, Asselin B, et al. Outcome of children with Standard-Risk T-Lineage acute lymphoblastic leukemia–comparison among different treatment strategies. Pediatr Blood Cancer. 2016;63(2):255–261.
   PubMed Web of Science ®Google Scholar
• Cui L, Li ZG, Chai YH, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: the first nation-wide prospective multicenter study in China. Am J Hematol. 2018;93(7):913–920.
   PubMed Web of Science ®Google Scholar
• Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (EGIL). Leukemia. 1995;9(10):1783–1786.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Möricke A, Reiter A, et al. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. Klin Padiatr. 2013;225(S 01):S62–S72.
   PubMedGoogle Scholar
• Gao C, Liu SG, Yue ZX, et al. Clinical-biological characteristics and treatment outcomes of pediatric pro-B ALL patients enrolled in BCH-2003 and CCLG-2008 protocol: a study of 121 Chinese children. Cancer Cell Int. 2019;19(1):293.
   PubMed Web of Science ®Google Scholar
• Wei W, Chen X, Zou Y, et al. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China. BMC Pediatr. 2015;15;15(1):80.
   PubMedGoogle Scholar
• Hu YX, Lu J, He HL, et al. A prospective evaluation of minimal residual disease as risk stratification for CCLG-ALL-2008 treatment protocol in pediatric B precursor acute lymphoblastic leukemia. Eur Rev Med Pharmacol Sci. 2016;20(9):1680–1690.
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730–2741.
   PubMed Web of Science ®Google Scholar
• Prentice RL, Zhao S. Nonparametric estimation of the multivariate survivor function: the multivariate Kaplan-Meier estimator. Lifetime Data Anal. 2018;24(1):3–27.
   PubMed Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163–170.
   PubMedGoogle Scholar
• Cox DR. Regression models and life tables. J R Stat Soc. 1972;34(2):187–202.
   Google Scholar
• Etoposide. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
   Google Scholar
• Ochs MA, Perissinotti AJ, Marini BL, et al. Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia. Leuk Res. 2021;102:106517.
   PubMed Web of Science ®Google Scholar
• Liu X, Zou Y, Zhang L, et al. A novel risk defining system for pediatric T-Cell acute lymphoblastic leukemia from CCCG-ALL-2015 group. Front Oncol. 2022;12:841179.
   PubMed Web of Science ®Google Scholar
• Inaba H, Pui CH. Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer Metastasis Rev. 2019;38(4):595–610.
   PubMed Web of Science ®Google Scholar
• Jeha S, Pei D, Choi J, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16. J Clin Oncol. 2019;37(35):3377–3391.
   PubMed Web of Science ®Google Scholar
• Hagedorn N, Acquaviva C, Fronkova E, et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the resistant disease committee of the international BFM study group. Blood. 2007;110(12):4022–4029.
   PubMed Web of Science ®Google Scholar
• Vosberg S, Greif PA. Clonal evolution of acute myeloid leukemia from diagnosis to relapse. Genes Chromosomes Cancer. 2019;58(12):839–849.
   PubMed Web of Science ®Google Scholar
• Pui CH, Pei D, Cheng C, et al. Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-Delta T-cell receptor. Oncoimmunology. 2019;8(8):1599637.
   PubMed Web of Science ®Google Scholar
• Szczepański T, Pongers-Willemse MJ, Langerak AW, et al. Unusual immunoglobulin and T-cell receptor gene rearrangement patterns in acute lymphoblastic leukemias. Curr Top Microbiol Immunol. 1999;246:205–213.
   PubMed Web of Science ®Google Scholar
• Minden MD, Toyonaga B, Ha K, et al. Somatic rearrangement of T-cell antigen receptor gene in human T-cell malignancies. Proc Natl Acad Sci USA. 1985;82(4):1224–1227.
   PubMed Web of Science ®Google Scholar
• Olshanskaya Y, Kazakova A, Tsaur G, et al. Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB). Leuk Lymphoma. 2019;60(2):426–432.
   PubMed Web of Science ®Google Scholar
• Graux C, Cools J, Michaux L, et al. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20(9):1496–1510.
   PubMed Web of Science ®Google Scholar
• Mrózek K, Harper DP, Aplan PD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23(5):991–1010, v.
   PubMed Web of Science ®Google Scholar
• Harrison CJ, Foroni L. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev Clin Exp Hematol. 2002;6(2):91–113.
   PubMedGoogle Scholar
• Onciu M, Lai R, Vega F, et al. Precursor T-cell acute lymphoblastic leukemia in adults: age-related immunophenotypic, cytogenetic, and molecular subsets. Am J Clin Pathol. 2002;117(2):252–258.
   PubMed Web of Science ®Google Scholar
• Bond J, Touzart A, Leprêtre S, et al. DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. Haematologica. 2019;104(8):1617–1625.
   PubMed Web of Science ®Google Scholar
• Kanayama T, Imamura T, Kawabe Y, et al. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia. Int J Hematol. 2018;108(6):665–669.
   PubMed Web of Science ®Google Scholar
• Bartram J, Patel B, Fielding AK. Monitoring MRD in ALL: methodologies, technical aspects and optimal time points for measurement. Semin Hematol. 2020;57(3):142–148.
   PubMed Web of Science ®Google Scholar
• Jain N, Lamb AV, O’Brien S, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127(15):1863–1869.
   PubMed Web of Science ®Google Scholar
• Noronha EP, Marques LVC, Andrade FG, et al. The profile of immunophenotype and genotype aberrations in subsets of pediatric T-Cell acute lymphoblastic leukemia. Front Oncol. 2019;9:316.
   PubMed Web of Science ®Google Scholar
• Sayed DM, Sayed HAR, Raslan HN, et al. Outcome and clinical significance of immunophenotypic markers expressed in different treatment protocols of pediatric patients with T-ALL in developing countries. Clin Lymphoma Myeloma Leuk. 2017;17(7):443–449.
   PubMed Web of Science ®Google Scholar